Truist raised the firm’s price target on Quest Diagnostics (DGX) to $225 from $220 and keeps a Hold rating on the shares after its Q1 earnings beat. Core trends were strong with organic volumes nicely ahead aided by FMS/Corewell and core tests remaining a nice tailwind, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $220 from $210 at UBS
- Quest Diagnostics price target raised to $229 from $224 at Baird
- Quest Diagnostics price target raised to $245 from $225 at BofA
- Quest Diagnostics price target raised to $230 from $225 at Barclays
- Quest Diagnostics Lifts Outlook On Strong Earnings Call